HomeCompareTHTX vs SBUX

THTX vs SBUX: Dividend Comparison 2026

THTX yields 59.00% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 THTX wins by $453.2K in total portfolio value
10 years
THTX
THTX
● Live price
59.00%
Share price
$3.39
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$620.2K
Annual income
$143,088.77
Full THTX calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — THTX vs SBUX

📍 THTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTHTXSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, THTX + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
THTX pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

THTX
Annual income on $10K today (after 15% tax)
$5,014.75/yr
After 10yr DRIP, annual income (after tax)
$121,625.45/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, THTX beats the other by $61,159.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of THTX + SBUX for your $10,000?

THTX: 50%SBUX: 50%
100% SBUX50/50100% THTX
Portfolio after 10yr
$393.6K
Annual income
$107,112.61/yr
Blended yield
27.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

THTX
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Altman Z
-8.8
Piotroski
5/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

THTX buys
0
SBUX buys
0
No recent congressional trades found for THTX or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTHTXSBUX
Forward yield59.00%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$620.2K$167.0K
Annual income after 10y$143,088.77$71,136.45
Total dividends collected$512.6K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: THTX vs SBUX ($10,000, DRIP)

YearTHTX PortfolioTHTX Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$16,600$5,899.71$11,121$420.68+$5.5KTHTX
2$26,914$9,152.65$12,548$648.40+$14.4KTHTX
3$42,667$13,869.04$14,440$1,013.98+$28.2KTHTX
4$66,202$20,548.25$17,068$1,617.30+$49.1KTHTX
5$100,633$29,796.73$20,912$2,649.52+$79.7KTHTX
6$150,008$42,330.45$26,875$4,499.29+$123.1KTHTX
7$219,480$58,971.49$36,771$8,014.12+$182.7KTHTX
8$315,482$80,637.85$54,542$15,197.11+$260.9KTHTX
9$445,892$108,326.32$89,602$31,242.49+$356.3KTHTX
10$620,193$143,088.77$167,011$71,136.45+$453.2KTHTX

THTX vs SBUX: Complete Analysis 2026

THTXStock

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Full THTX Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this THTX vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

THTX vs SCHDTHTX vs JEPITHTX vs OTHTX vs KOTHTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.